Références :

  1. Thies F, Pillon C, Moliere P, Lagarde M, Lecerf J. Preferential incorporation of sn-2 lysoPC DHA over unesterified DHA in the young rat brain. Am J Physiol. 1994 Nov;267(5 Pt 2):R1273-9.
  2. Bernoud N, Fenart L, Molière P, Dehouck MP, Lagarde M, Cecchelli R, Lecerf J. Preferential transfer of 2-docosahexaenoyl-1-lysophosphatidylcholine through an in vitro blood-brain barrier over unesterified docosahexaenoic acid. J Neurochem. 1999 Jan;72(1):338-45.
  3. Polette A, Deshayes C, Chantegrel B, Croset M, Armstrong JM, Lagarde M. Synthesis of acetyl,docosahexaenoyl-glycerophosphocholine and its characterization using nuclear magnetic resonance. Lipids. 1999 Dec;34(12):1333-7.
  4. Croset M, Brossard N, Polette A, Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J. 2000 Jan 1;345 Pt 1:61-7.
  5. Lagarde M, Bernoud N, Brossard N, Lemaitre-Delaunay D, Thiès F, Croset M, Lecerf Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci. 2001 Apr-Jun;16(2-3):201-4; discussion 215-21. Review.
  6. Picq M, Chen P, Perez M, Michaud M, Véricel E, Guichardant M, Lagarde M. DHA metabolism: targeting the brain and lipoxygenation. Mol Neurobiol. 2010 Aug;42(1):48-51. Review.
  7. Chauveau F, Cho TH, Perez M, Guichardant M, Riou A, Aguettaz P, Picq M, Lagarde M, Berthezène Y, Nighoghossian N, Wiart M. Brain-targeting form of docosahexaenoic acid for experimental stroke treatment: MRI evaluation and anti-oxidant impact. Curr Neurovasc Res. 2011 May;8(2):95-102.
  8. Lagarde M, Hachem M, Bernoud-Hubac N, Picq M, Véricel E, Guichardant M. Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain. Prostaglandins Leukot Essent Fatty Acids. 2015 Jan;92:63-5. Review.
  9. Hachem M, Géloën A, Van AL, Foumaux B, Fenart L, Gosselet F, Da Silva P, Breton G, Lagarde M, Picq M, Bernoud-Hubac N. Efficient Docosahexaenoic Acid Uptake by the Brain from a Structured Phospholipid. Mol Neurobiol. 2016 Jul;53(5):3205-15.
  10. Belkouch M, Hachem M, Elgot A, Van AL, Picq M, Guichardant M, Lagarde M, Bernoud-Hubac N. The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer’s disease. J Nutr Biochem. 2016 Dec;38:1-11.
  11. Nouveau dépôt de brevet sur AceDoPC® comme précurseur d’acétylcholine, pour le traitement des maladies acétylcholine-dépendantes, dont la Maladie d’Alzheimer.
LipTher®